Good post, most probably ignored him after that. Right now I personally just have him in the overzealous upon hearing some info category, more time will tell. With BP and cancer, phase 2 to approval is low, so no secret we probably would not get a good evaluation now, especially with no clinical data from leronlimab. As more different cancers phase 2 are approved, maybe it becomes more interesting. Now with good ctc numbers, everything changes imo.

Also there are three BPs working with Ccr5 & Cancer, BMS just added an arm to a 2 year trial in one cancer, my guess is from having good data in their other trial, So some BPs have the data, and seem to be given credibility to Ccr5/cancer. One like Gilead, probably wouldn’t give value much without data, so probably depends on the interested BP. It would have been great to have some data now, but if they can’t agree on cancer, breaking that off, if possible, would benefit Cydy the most in my opinion. Because the possibility to me is much bigger than even mono.